Explore more publications!
Healthcare Weekly Jamaica
Got News to Share?

Healthcare Weekly Jamaica: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Weekly Jamaica.

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

Press releases published on February 2, 2026

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
Feb. 2, 2026

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”

Indeterminate GlobeNewswire
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
Feb. 2, 2026

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Indeterminate GlobeNewswire
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Feb. 2, 2026

Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Indeterminate GlobeNewswire
CorMedix Therapeutics Announces Share Repurchase Program
Feb. 2, 2026

CorMedix Therapeutics Announces Share Repurchase Program

Indeterminate GlobeNewswire
Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.
Feb. 2, 2026

Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.

Indeterminate GlobeNewswire
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
Feb. 2, 2026

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Indeterminate GlobeNewswire
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Feb. 2, 2026

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

Indeterminate GlobeNewswire
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
Feb. 2, 2026

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Indeterminate GlobeNewswire
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
Feb. 2, 2026

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Indeterminate GlobeNewswire
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Feb. 2, 2026

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Indeterminate GlobeNewswire
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
Feb. 2, 2026

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

Indeterminate GlobeNewswire
DLH to Announce Fiscal 2026 First Quarter Financial Results
Feb. 2, 2026

DLH to Announce Fiscal 2026 First Quarter Financial Results

Indeterminate GlobeNewswire
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
Feb. 2, 2026

Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians

Indeterminate GlobeNewswire
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
Feb. 2, 2026

ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan

Indeterminate GlobeNewswire
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
Feb. 2, 2026

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Indeterminate GlobeNewswire
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
Feb. 2, 2026

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

Indeterminate GlobeNewswire
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
Feb. 2, 2026

Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook

Indeterminate GlobeNewswire
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
Feb. 2, 2026

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

Indeterminate GlobeNewswire
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
Feb. 2, 2026

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease

Indeterminate GlobeNewswire
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
Feb. 2, 2026

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions